Transdisciplinary approach to restore pancreatic islet function

Immunologic Research

Volumn 57, Issue 1-3, 2013, Pages 210-221

  Fotino, Carmen ^a   Molano, R Damaris ^a   Ricordi, Camillo ^a,b,c   Pileggi, Antonello ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami College of Engineering   (United States)

Author keywords

Adenosine (Ado); ATP; Autoimmunity; Beta cell; Bioengineering; Bioluminiscence; CD39; CD73; Cell transplantation; Cellular therapies; Confocal microscopy; Diabetes; Diabetes mellitus; Engraftment; Hyperbaric oxygen therapy; Imaging; Immunotherapy; Implantable device; Inflammation; Innate immunity; Islet transplantation; Live imaging; Metabolic control; Noninvasive imaging; P2X7; Purinergic receptors; Rejection; Transplant microenvironment; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ARTICLE; BIOENGINEERING; CYTOLOGY; HUMAN; HYPERBARIC OXYGEN; IMAGING; IMMUNOBIOLOGY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELLULAR MICROENVIRONMENT; DIABETES MELLITUS, TYPE 1; HUMANS; HYPERBARIC OXYGENATION; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; SIGNAL TRANSDUCTION;

EID: 84891481458     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8437-4     Document Type: Article

References (128)

1. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. [database on the Internet]. U.S. Department of Health and Human Services, National Institute of Health. 2005. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index. htm. Accessed.
2. LeRoith D, Taylor SI, Olefsky JM. Diabetes mellitus: a fundamental and clinical text. III ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
3. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293-300.
4. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221-9. doi: 10.1016/s0140-6736(01)05415-0.
5. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011;60(1):1-8. doi: 10.2337/db10-1114.
6. Pileggi A, Alejandro R, Ricordi C. Clinical islet transplantation. Minerva Endocrinol. 2006;31(3):219-32.
7. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care. 2009;32(8):1563-9. doi: 10.2337/dc09-0490.
8. Piemonti L, Pileggi A. 25 years of the Ricordi automated method for islet isolation. CellR4. 2013;1(1):8-22.
9. Pileggi A, Cobianchi L, Inverardi L, Ricordi C. Overcoming the challenges now limiting islet transplantation: a sequential, integrated approach. Ann N Y Acad Sci. 2006;1079:383-98.
10. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947-57. doi: 10.2337/db09-0498.
11. Digon BJ III, Rother KI, Hirshberg B, Harlan DM. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care. 2003;26(11):3191.
12. Hirshberg B, Rother KI, Digon BJ III, Lee J, Gaglia JL, Hines K, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003;26(12):3288-95.
13. Cure P, Pileggi A, Froud T, Norris PM, Baidal DA, Cornejo A, et al. Alterations of the female reproductive system in recipients of islet grafts. Transplantation. 2004;78(11):1576-81.
14. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation. 2005;80(12):1718-28.
15. Molinari M, Al-Saif F, Ryan EA, Lakey JR, Senior PA, Paty BW, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant. 2005;5(11):2799-804.
16. Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation. 2003;76(11):1623-5.
17. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318-30.
18. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS the impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia. 2006;49(10):2341-9.
19. Zahr E, Molano RD, Pileggi A, Ichii H, Jose SS, Bocca N, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation. 2007;84(12):1576-83.
20. Fotino C, Ricordi C, Lauriola V, Alejandro R, Pileggi A. Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev Diabet Stud. 2010;7(2):144-57. doi: 10.1900/RDS.2010.7.144.
21. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol. 2009;106(3):988-95.
22. Vlodavsky E, Palzur E, Soustiel JF. Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury. Neuropathol Appl Neurobiol. 2006;32(1):40-50.
23. Wilson HD, Toepfer VE, Senapati AK, Wilson JR, Fuchs PN. Hyperbaric oxygen treatment is comparable to acetylsalicylic acid treatment in an animal model of arthritis. J Pain. 2007;8(12):924-30.
24. Wilson HD, Wilson JR, Fuchs PN. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res. 2006;1098(1):126-8.
25. Zhang Q, Chang Q, Cox RA, Gong X, Gould LJ. Hyperbaric oxygen attenuates apoptosis and decreases inflammation in an ischemic wound model. J Invest Dermatol. 2008;128(8):2102-12.
26. Gallagher KA, Goldstein LJ, Thom SR, Velazquez OC. Hyperbaric oxygen and bone marrow-derived endothelial progenitor cells in diabetic wound healing. Vascular. 2006;14(6):328-37.
27. Goldstein LJ, Gallagher KA, Bauer SM, Bauer RJ, Baireddy V, Liu ZJ, et al. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. Stem Cells (Dayton, Ohio). 2006;24(10):2309-18.
28. Liu ZJ, Velazquez OC. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal. 2008;10(11):1869-82.
29. Milovanova TN, Bhopale VM, Sorokina EM, Moore JS, Hunt TK, Hauer-Jensen M, et al. Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo. J Appl Physiol. 2009;106(2):711-28.
30. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transpl. 2008;17(12):1295-304.
31. Chen SY, Chen YC, Wang JK, Hsu HP, Ho PS, Chen YC, et al. Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB × NZW) F1 mice. Clin Immunol. 2003;108(2):103-10.
32. Sakata N, Chan NK, Ostrowski RP, Chrisler J, Hayes P, Kim S, et al. Hyperbaric oxygen therapy improves early posttransplant islet function. Pediatr Diabetes. 2010;11(7):471-8. doi: 10.1111/j.1399-5448.2009.00629.x.
33. Juang JH, Hsu BR, Kuo CH, Uengt SW. Beneficial effects of hyperbaric oxygen therapy on islet transplantation. Cell Transpl. 2002;11(2):95-101.
34. Faleo G, Fotino C, Bocca N, Molano RD, Zahr-Akrawi E, Molina J, et al. Prevention of autoimmune diabetes and induction of beta-cell proliferation in NOD mice by hyperbaric oxygen therapy. Diabetes. 2012;61(7):1769-78. doi: 10.2337/db11-0516.
35. Matzinger P. Introduction to the series. Danger model of immunity. Scand J Immunol. 2001;54(1-2):2-3.
36. Ribeiro MM, Klein D, Pileggi A, Molano RD, Fraker C, Ricordi C, et al. Heme oxygenase-1 fused to a TAT peptide transduces and protects pancreatic beta-cells. Biochem Biophys Res Commun. 2003;305(4):876-81.
37. Fornoni A, Cobianchi L, Sanabria NY, Pileggi A, Molano RD, Ichii H, et al the l-isoform but not d-isoforms of a JNK inhibitory peptide protects pancreatic beta-cells. Biochem Biophys Res Commun. 2007;354(1):227-33. doi: 10.1016/j.bbrc.2006.12.186.
38. Fornoni A, Pileggi A, Molano RD, Sanabria NY, Tejada T, Gonzalez-Quintana J, et al. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. Diabetologia. 2008;51(2):298-308. doi: 10.1007/s00125-007-0889-4.
39. Bravo-Egana V, Rosero S, Klein D, Jiang Z, Vargas N, Tsinoremas N, et al. Inflammation-mediated regulation of microRNA expression in transplanted pancreatic islets. J Transpl. 2012;2012:723614. doi: 10.1155/2012/723614.
40. Hogan AR, Doni M, Molano RD, Ribeiro MM, Szeto A, Cobianchi L, et al. Beneficial effects of ischemic preconditioning on pancreas cold preservation. Cell Transpl. 2012;21(7):1349-60. doi: 10.3727/096368911X623853.
41. Pileggi A, Klein D, Fotino C, Bravo-Engaña V, Doni M, Podetta M, et al. MicroRNAs in islet autoimmunity and transplantation. Immunol Res. 2013. doi: 10.1007/s12026-013-8436-5.
42. Cechin SR, Perez-Alvarez I, Fenjves E, Molano RD, Pileggi A, Berggren PO, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transpl. 2012;21(4):633-48. doi: 10.3727/096368911X576027.
43. Martins PN, Chandraker A, Tullius SG. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transpl Int. 2006;19(5):351-9. doi: 10.1111/j.1432-2277.2006.00301.x.
44. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004;364(9447):1814-27. doi: 10.1016/S0140-6736(04)17406-0.
45. Pratschke J, Tullius SG, Neuhaus P. Brain death associated ischemia/reperfusion injury. Ann Transpl. 2004;9(1):78-80.
46. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol. 1996;155(6):1831-40.
47. Pileggi A, Molano RD, Berney T, Ichii H, San Jose S, Zahr E, et al. Prolonged allogeneic islet graft survival by protoporphyrins. Cell Transpl. 2005;14(2-3):85-96.
48. Pileggi A, Molano RD, Berney T, Cattan P, Vizzardelli C, Oliver R, et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes. 2001;50(9):1983-91.
49. Molano RD, Pileggi A, Song S, Zahr E, San Jose S, Molina J, et al. Prolonged islet allograft survival by alpha-1 antitrypsin: the role of humoral immunity. Transpl Proc. 2008;40(2):455-6. doi: 10.1016/j.transproceed.2008.02. 009.
50. Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, Cai SX, et al. Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival. Diabetes. 2010;59(6):1469-77. doi: 10.2337/db09-0502.
51. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 Update from the collaborative Islet transplant registry. Transplantation. 2008;86(12):1783-8.
52. Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transpl. 2010;10(9):2082-91. doi: 10.1111/j.1600-6143.2010.03212.x.
53. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830-5. doi: 10.1001/jama.293.7.830.
54. Fotino C, Pileggi A. Blockade of leukocyte function antigen-1 (LFA-1) in clinical islet transplantation. Curr Diab Rep. 2011;11(5):337-44. doi: 10.1007/s11892-011-0214-y.
55. Chowdhury SA, Nagata M, Yamada K, Nakayama M, Chakrabarty S, Jin Z, et al. Tolerance mechanisms in murine autoimmune diabetes induced by anti-ICAM-1/LFA-1 mAb and anti-CD8 mAb. Kobe J Med Sci. 2002;48(5-6):167-75.
56. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol. 1994;6(6):831-8.
57. Ninova D, Dean PG, Stegall MD. Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. J Autoimmun. 2004;23(3):201-9. doi: 10.1016/j.jaut.2004.07.002.
58. Berney T, Pileggi A, Molano RD, Poggioli R, Zahr E, Ricordi C, et al the effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation. 2003;76(12):1669-74. doi: 10.1097/01.TP.0000092525.17025.D0.
59. Molano RD, Berney T, Li H, Cattan P, Pileggi A, Vizzardelli C, et al. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes. 2001;50(2):270-6.
60. Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transpl. 2007;16(8):787-98.
61. Molano RD, Pileggi A, Berney T, Poggioli R, Zahr E, Oliver R, et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes. 2003;52(4):957-64.
62. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal. 2008;1(39):ra6. doi: 10.1126/scisignal.1160583.
63. Robson SC, Sevigny J, Zimmermann H the E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006;2(2):409-30. doi: 10.1007/s11302-006-9003- 5.
64. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 2012;36(3):362-73. doi: 10.1016/j.immuni.2011.12.019.
65. Placido R, Auricchio G, Falzoni S, Battistini L, Colizzi V, Brunetti E, et al. P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability. Cell Immunol. 2006;244(1):10-8. doi: 10.1016/j.cellimm.2007.02.001.
66. Beigi RD, Kertesy SB, Aquilina G, Dubyak GR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol. 2003;140(3):507-19. doi: 10.1038/sj.bjp.0705470.
67. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol. 2005;174(2):1073-80.
68. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-65. doi: 10.1084/jem.20062512.
69. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3 + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225-32. doi: 10.1182/blood-2006-12-064527.
70. Romio M, Reinbeck B, Bongardt S, Huls S, Burghoff S, Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol. 2011;301(2):C530-9. doi: 10.1152/ajpcell.0 0385.2010.
71. Ghaemi Oskouie F, Shameli A, Yang A, Desrosiers MD, Mucsi AD, Blackburn MR, et al. High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J Immunol. 2011;186(12):6798-806. doi: 10.4049/jimmunol.1004222.
72. Vergani A, Fotino C, D'Addio F, Tezza S, Podetta M, Gatti F, et al. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes. 2013;62(5):1665-75. doi: 10.2337/db12-0242.
73. Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, Niewczas M, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation. 2013;127(4):463-75. doi: 10.1161/CIRCULATIONAHA.112. 123653.
74. Jacques-Silva MC, Correa-Medina M, Cabrera O, Rodriguez-Diaz R, Makeeva N, Fachado A, et al. ATP-gated P2X3 receptors constitute a positive autocrine signal for insulin release in the human pancreatic beta cell. Proc Natl Acad Sci USA. 2010;107(14):6465-70. doi: 10.1073/pnas.0908935107.
75. Kittel A, Garrido M, Varga G. Localization of NTPDase1/CD39 in normal and transformed human pancreas. J Histochem Cytochem. 2002;50(4):549-56.
76. Ricordi C. Islet transplantation: a brave new world. Diabetes. 2003;52(7):1595-603.
77. Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9(6):486-91.
78. Scharp DW, Marchetti P, Swanson C, Newton M, McCullough CS, Olack B the effect of transplantation site and islet mass on long-term survival and metabolic and hormonal function of canine purified islet autografts. Cell Transpl. 1992;1(2-3):245-54.
79. Ricordi C, Scharp DW, Lacy PE. Reversal of diabetes in nude mice after transplantation of fresh and 7-day-cultured (24 C) human pancreatic islets. Transplantation. 1988;45(5):994-6.
80. Lanza RP, Borland KM, Lodge P, Carretta M, Sullivan SJ, Muller TE, et al. Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas. Diabetes. 1992;41(7):886-9.
81. Petruzzo P, Pibiri L, De Giudici MA, Basta G, Calafiore R, Falorni A, et al. Xenotransplantation of microencapsulated pancreatic islets contained in a vascular prosthesis: preliminary results. Transpl Int. 1991;4(4):200-4.
82. Pileggi A, Molano RD, Ricordi C, Zahr E, Collins J, Valdes R, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006;81(9):1318-24.
83. Yasunami Y, Lacy PE, Finke EH. A new site for islet transplantation - a peritoneal-omental pouch. Transplantation. 1983;36(2):181-2.
84. Guan J, Zucker PF, Atkison P, Behme MT, Dupre J, Stiller CR. Liver-omental pouch and intrahepatic islet transplants produce portal insulin delivery and prevent hyperinsulinemia in rats. Transpl Proc. 1995;27(6):3236.
85. Guan J, Behme MT, Zucker P, Atkison P, Hramiak I, Zhong R, et al. Glucose turnover and insulin sensitivity in rats with pancreatic islet transplants. Diabetes. 1998;47(7):1020-6.
86. Kin T, Korbutt GS, Rajotte RV. Survival and metabolic function of syngeneic rat islet grafts transplanted in the omental pouch. Am J Transpl. 2003;3(3):281-5.
87. Kenyon NS, Berman DM, O'Neil JJ, Kenyon NM, Zimmerman M, Pileggi A, et al. Survival and function of allogeneic islets implanted in an omental pouch in cynomolgus monkeys (Macaca fascicularis). Xenotransplantation. 2007;14(5):406.
88. Ao Z, Matayoshi K, Yakimets WJ, Katyal D, Rajotte RV, Warnock GL. Development of an omental pouch site for islet transplantation. Transpl Proc. 1992;24(6):2789.
89. Ao Z, Matayoshi K, Lakey JR, Rajotte RV, Warnock GL. Survival and function of purified islets in the omental pouch site of outbred dogs. Transplantation. 1993;56(3):524-9.
90. Simeonovic CJ, Dhall DP, Wilson JD, Lafferty KJ. A comparative study of transplant sites for endocrine tissue transplantation in the pig. Aust J Exp Biol Med Sci. 1986;64(Pt 1):37-41.
91. Weber CJ, Hardy MA, Pi-Sunyer F, Zimmerman E, Reemtsma K. Tissue culture preservation and intramuscular transplantation of pancreatic islets. Surgery. 1978;84(1):166-74.
92. Rafael E, Tibell A, Ryden M, Lundgren T, Savendahl L, Borgstrom B, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transpl. 2008;8(2):458-62.
93. Speier S, Nyqvist D, Cabrera O, Yu J, Molano RD, Pileggi A, et al. Noninvasive in vivo imaging of pancreatic islet cell biology. Nat Med. 2008;14(5):574-8.
94. Abdulreda MH, Faleo G, Molano RD, Lopez-Cabezas M, Molina J, Tan Y, et al. High-resolution, noninvasive longitudinal live imaging of immune responses. Proc Natl Acad Sci USA. 2011;108(31):12863-8. doi: 10.1073/pnas.1105002108.
95. Perez VL, Caicedo A, Berman DM, Arrieta E, Abdulreda MH, Rodriguez-Diaz R, et al the anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes. Diabetologia. 2011;54(5):1121-6. doi: 10.1007/s00125-011-2091-y.
96. Kakabadze Z, Gupta S, Pileggi A, Molano RD, Ricordi C, Shatirishvili G, et al. Correction of diabetes mellitus by transplanting minimal mass of syngeneic islets into vascularized small intestinal segment. Am J Transpl. 2013. doi: 10.1111/ajt.12412.
97. Joseph B, Berishvili E, Benten D, Kumaran V, Liponava E, Bhargava K, et al. Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. Nat Med. 2004;10(7):749-53.
98. Cantarelli E, Melzi R, Mercalli A, Sordi V, Ferrari G, Lederer CW, et al. Bone marrow as an alternative site for islet transplantation. Blood. 2009;114(20):4566-74. doi: 10.1182/blood-2009-03-209973.
99. Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep. 2011;11(5):364-74. doi: 10.1007/s11892-011-0216-9.
100. Brady AC, Martino MM, Pedraza E, Sukert S, Pileggi A, Ricordi C, et al. Proangiogenic hydrogels within macroporous scaffolds enhance islet engraftment in an extrahepatic site. Tissue Eng Part A. 2013. doi: 10.1089/ten.TEA.2012. 0686.
101. Wang Y, Lanzoni G, Carpino G, Cui CB, Dominguez-Bendala J, Wauthier E, et al. Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis. Stem cells (Dayton, Ohio). 2013. doi: 10.1002/stem.1460.
102. Rafael E, Tibell A, Ryden M, Lundgren T, Savendahl L, Borgstrom B, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant. 2008;8(2):458-62. doi: 10.1111/j.1600-6143. 2007.02060.x.
103. Dardenne S, Sterkers A, Leroy C, Da Mata L, Zerbib P, Pruvot FR, et al. Laparoscopic spleen-preserving distal pancreatectomy followed by intramuscular autologous islet transplantation for traumatic pancreatic transection in a young adult. JOP. 2012;13(3):285-8.
104. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 year after xenotransplantation. Xenotransplantation. 2007;14(2):157-61. doi: 10.1111/j.1399-3089.2007.00384.x.
105. Basta G, Montanucci P, Luca G, Boselli C, Noya G, Barbaro B, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care. 2011;34(11):2406-9. doi: 10.2337/dc11-0731.
106. Maffi P, Balzano G, Ponzoni M, Nano R, Sordi V, Melzi R, et al. Autologous pancreatic islet transplantation in human bone marrow. Diabetes. 2013. doi: 10.2337/db13-0465.
107. Berman DM, O'Neil JJ, Coffey LC, Chaffanjon PC, Kenyon NM, Ruiz P Jr, et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant. 2009;9(1):91-104. doi: 10.1111/j.1600-6143.2008.02489.x.
108. Pedraza E, Brady AC, Fraker CA, Molano RD, Sukert S, Berman DM, et al. Macroporous three-dimensional PDMS scaffolds for extrahepatic islet transplantation. Cell Transpl. 2013;22(7):1123-35. doi: 10.3727/ 096368912X657440.
109. Giuliani M, Moritz W, Bodmer E, Dindo D, Kugelmeier P, Lehmann R, et al. Central necrosis in isolated hypoxic human pancreatic islets: evidence for postisolation ischemia. Cell Transpl. 2005;14(1):67-76.
110. Moritz W, Meier F, Stroka DM, Giuliani M, Kugelmeier P, Nett PC, et al. Apoptosis in hypoxic human pancreatic islets correlates with HIF-1alpha expression. Faseb J. 2002;16(7):745-7.
111. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, et al. XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes. 2005;54(9):2541-8.
112. Li X, Chen H, Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem. 2004;279(1):765-71.
113. Bocca N, Ricordi C, Kenyon NS, Latta P, Buchwald P. 3-D multiphysics FEM modeling to optimize local drug delivery in a biohybrid device designed for cell transplant. In: Proceedings of the Comsol Conference. 2007. p. 101-7.
114. Bocca N, Pileggi A, Molano RD, Marzorati S, Wu W, Bodor N, et al. Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate in islet transplantation. Pharmazie. 2008;63(3):226-32.
115. Buchwald P, Bocca N, Marzorati S, Hochhaus G, Bodor N, Stabler C, et al. Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. Pharmazie. 2010;65(6):421-8.
116. Ahlgren U, Gotthardt M. Approaches for imaging islets: recent advances and future prospects. Adv Exp Med Biol. 2010;654:39-57.
117. Berney T, Toso C. Monitoring of the islet graft. Diabetes Metab. 2006;32(5 Pt 2):503-12.
118. Medarova Z, Moore A. MRI as a tool to monitor islet transplantation. Nat Rev. 2009;5(8):444-52.
119. Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, et al. Positron emission tomography in clinical islet transplantation. Am J Transpl. 2009;9(12):2816-24.
120. Eriksson O, Jahan M, Johnstrom P, Korsgren O, Sundin A, Halldin C, et al. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol. 2010;37(3):357-63.
121. Prescher JA, Contag CH. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr Opin Chem Biol. 2010;14(1):80-9.
122. Speier S, Nyqvist D, Kohler M, Caicedo A, Leibiger IB, Berggren PO. Noninvasive high-resolution in vivo imaging of cell biology in the anterior chamber of the mouse eye. Nat Protoc. 2008;3(8):1278-86.
123. Martinic MM, von Herrath MG. Real-time imaging of the pancreas during development of diabetes. Immunol Rev. 2008;221:200-13.
124. Nyman LR, Wells KS, Head WS, McCaughey M, Ford E, Brissova M, et al. Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. J Clin Investig. 2008;118(11):3790-7.
125. Molano RD, Abdulreda M, Faleo G, Molina J, Berggren PO, Ricordi C, et al. Allogeneic islet transplantation in the anterior chamber of the eye for in vivo studies of islet immunobiology. Diabetes. 2009;58:A499.
126. Nyqvist D, Speier S, Rodriguez-Diaz R, Molano RD, Lipovsek S, Rupnik M, et al. Donor islet endothelial cells in pancreatic islet revascularization. Diabetes. 2011;60(10):2571-7. doi: 10.2337/db10-1711.
127. Fan Z, Spencer JA, Lu Y, Pitsillides CM, Singh G, Kim P, et al. In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response. Nat Med. 2010;16(6):718-22.
128. Abdulreda MH, Caicedo A, Berggren PO. A natural body window to study human pancreatic islet function and survival. CellR4. 2013;1(2):111-22.